PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-10.40%
Both companies show declining cash positions (-10.40% vs AXSM's -4.58%). Seth Klarman would examine if this reflects broader market conditions or operational challenges.
No Data
No Data available this quarter, please select a different quarter.
-10.40%
Cash + STI yoy ≥ 1.5x AXSM's -4.58%. David Dodd might see it as a strategic cash buffer advantage. Evaluate deployment plans.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Other current assets growth < half of AXSM's 33.64%. David Dodd sees a leaner approach to short-term items.
-10.80%
Below half of AXSM's 1.97%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
-9.91%
Below half AXSM's 290.38%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
0.93%
Less than half of AXSM's 15.37%. David Dodd sees fewer expansions in non-core assets. Possibly a simpler focus.
-8.44%
Below half of AXSM's 22.30%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-10.73%
Below half of AXSM's 4.96%. Michael Burry sees a potential red flag for stagnation or capital shortage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-13.85%
Less than half of AXSM's 332.21%. David Dodd sees fewer expansions in other current obligations.
-12.74%
Less than half of AXSM's 6.00%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-0.42%
Less than half of AXSM's 6.46%. David Dodd sees a more conservative approach to non-current liabilities.
No Data
No Data available this quarter, please select a different quarter.
-2.69%
Less than half of AXSM's 6.25%. David Dodd sees far fewer liability expansions relative to competitor.
No Data
No Data available this quarter, please select a different quarter.
-4.24%
0.75-0.9x AXSM's -5.29%. Bill Ackman questions if competitor reinvests profits more robustly.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.56%
≥ 1.5x AXSM's -6.68%. David Dodd sees stronger capital base growth than competitor.
-10.73%
Below half AXSM's 4.96%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-8.90%
Less than half of AXSM's 8.53%. David Dodd sees less overall debt expansion vs. competitor.
10.43%
Less than half of AXSM's 25.25%. David Dodd sees better deleveraging or stronger cash buildup than competitor.